Tango Therapeutics, Inc. (TNGX) is a publicly traded Healthcare sector company. As of July 26, 2026, TNGX trades at $26.63 with a market cap of $4.34B and a P/E ratio of -30.59. TNGX moved -3.02% today. Year to date, TNGX is +200.56%; over the trailing twelve months it is +294.52%. Its 52-week range spans $1.03 to $34.39. Analyst consensus is strong buy with an average price target of $42.67. Rallies surfaces TNGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tango Therapeutics Adds Oncology Veteran Robert Azelby to Board to Advance Vopimetostat's Late-Stage Development: Tango Therapeutics appointed Robert Azelby, a biopharmaceutical leader with over 30 years of oncology commercialization and corporate strategy experience, to its Board of Directors. His expertise aims to support advancement of vopimetostat, its investigational PRMT5 inhibitor targeting MTAP-deleted cancers, toward potential late-stage development for pancreatic cancer.
| Metric | Value |
|---|---|
| Price | $26.63 |
| Market Cap | $4.34B |
| P/E Ratio | -30.59 |
| EPS | $-0.87 |
| Dividend Yield | 0.00% |
| 52-Week High | $34.39 |
| 52-Week Low | $1.03 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $62.38M |
| Net Income | $-101.59M |
| Gross Margin | 0.00% |
12 analysts cover TNGX: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $42.67.